$KTTA
Pasithea Therapeutics Corp.

2021 Q3 Form 10-Q Financial Statement

#000121390021060610 Filed on November 18, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q4 2020 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.274M
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.274M
YoY Change
Operating Profit -$1.274M
YoY Change
Interest Expense -$252.5K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$252.5K
YoY Change
Pretax Income -$1.526M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.526M
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$116.9K
COMMON SHARES
Basic Shares Outstanding 8.956M shares
Diluted Shares Outstanding 8.956M shares

Balance Sheet

Concept 2021 Q3 2020 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.57M
YoY Change
Cash & Equivalents $20.57M $243.7K
Short-Term Investments
Other Short-Term Assets $468.5K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.03M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $8.570K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $8.570K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $21.03M
Total Long-Term Assets $8.570K
Total Assets $21.04M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $528.1K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $528.1K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $4.039M
YoY Change
Total Long-Term Liabilities $4.039M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $528.1K
Total Long-Term Liabilities $4.039M
Total Liabilities $4.567M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.48M $241.4K
YoY Change
Total Liabilities & Shareholders Equity $21.04M
YoY Change

Cashflow Statement

Concept 2021 Q3 2020 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income -$1.526M
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$548.5K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$8.570K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$8.570K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.55M
YoY Change
NET CHANGE
Cash From Operating Activities -548.5K
Cash From Investing Activities -8.570K
Cash From Financing Activities 20.55M
Net Change In Cash 20.00M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$548.5K
Capital Expenditures -$8.570K
Free Cash Flow -$539.9K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001841330
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
USD
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
USD
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
USD
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
USD
us-gaap Share Based Compensation
ShareBasedCompensation
USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD

Files In Submission

Name View Source Status
R6.htm Edgar Link pending
0001213900-21-060610-index-headers.html Edgar Link pending
0001213900-21-060610-index.html Edgar Link pending
0001213900-21-060610.txt Edgar Link pending
0001213900-21-060610-xbrl.zip Edgar Link pending
f10q0921ex31-1_pasithea.htm Edgar Link pending
f10q0921ex31-2_pasithea.htm Edgar Link pending
f10q0921ex32-1_pasithea.htm Edgar Link pending
f10q0921ex32-2_pasithea.htm Edgar Link pending
f10q0921_pasitheatherap.htm Edgar Link pending
f10q0921_pasitheatherap_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ktta-20210930.xsd Edgar Link pending
ktta-20210930_cal.xml Edgar Link unprocessable
ktta-20210930_def.xml Edgar Link unprocessable
ktta-20210930_lab.xml Edgar Link unprocessable
ktta-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending